1-(4-Fluorophenyl)-3-methylazetidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 1-(4-Fluorophenyl)-3-methylazetidine
• 英文别名: 1-(4-fluorophenyl)-3-methylazetidine
• 化学式: C₁₀H₁₂FN
• 分子量: 165.21
• InChiKey: FRNMZNRCTPRDIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20160067245A1

  公开（公告）日：2016-03-10

  The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及使用新型三唑并[4,3-a]吡啶衍生物（公式（I）中所有基团如权利要求所定义）治疗各种中枢神经系统疾病的方法。本发明所述化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经系统和精神障碍以及涉及代谢型受体亚型mGluR2的疾病。本发明还涉及包含此类化合物的制药组合物、制备此类化合物和组合物的过程以及使用此类化合物预防或治疗涉及mGluR2的神经系统和精神障碍和疾病的方法。